Cumulative mean numbers of confirmed (plasma glucose ≤3

Slides:

Advertisements

Similar presentations

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Advertisements

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

Nat. Rev. Nephrol. doi: /nrneph

with undiagnosed diabetes mellitus by three diagnostic criteria

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Cumulative incidences of events, according to glucose-control strategy

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Completed and ongoing CVOTs (6–14,39,44–58)

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

A: PPG increment at week 26 for mealtime faster aspart versus IAsp.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Glucose, insulin, and AGE levels during an OGC before and after RT

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Zn2+ and NAD(P)H content in Mafa∆panc and Mafa∆panc;Mafb+/− β-cells.

The effect of PAD and infection on outcome of cast treatment

The underlying physiological basis of the HOMA model.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Adoptive transfer of purified activated G9Cα−/−

Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA. Stratified analysis of the association.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Graph showing percentage of total patients with PTD or IGT that would be detected in each category of FBG if an oral glucose tolerance test were performed.

Correlations between leptin DNA methylation and 2-h post-OGTT glucose levels, within the IGT group (A and B), leptin DNA methylation and mRNA levels (C.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

A: Probability of SICH by baseline glucose level.

Mean (± SE) plasma glucose concentrations, symptom scores, plasma epinephrine and glucagon concentrations, and relative rCBF (as measured by PET counts)

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Distribution of daily frequency of BGM

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Elevated blood glucose vs time.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

A: Glucose levels during basal-bolus and SSI treatment.

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.

Presentation transcript:

Cumulative mean numbers of confirmed (plasma glucose ≤3 Cumulative mean numbers of confirmed (plasma glucose ≤3.9 mmol/L [70 mg/dL]) or severe hypoglycemic events per participant during the main 6-month treatment period in the safety population. Cumulative mean numbers of confirmed (plasma glucose ≤3.9 mmol/L [70 mg/dL]) or severe hypoglycemic events per participant during the main 6-month treatment period in the safety population. A: Nocturnal events. B: Events at any time of day or night (24 h). Matthew C. Riddle et al. Dia Care 2014;37:2755-2762 ©2014 by American Diabetes Association